Table 1.
Clinical Trial Characteristics
| Reference | Design | N | Baseline IRLS Mean+SD | Follow-up (weeks) | Drug/Dose | Adjusted Mean Difference IRLS Mean+SE | Treatment CGI-I Responder Rate (%) | Jadad Score |
| Allen (2004)17 | P, R, DB, PC | 55 | N/A | 12 | Ropinirole 0.25–4.0 mg/d | –1.2±2.1 | Ropinirole=17/32 (53) Placebo=17/33 (52) |
3 |
| Stiasny-Kolster (2004)18 | P, R, DB, PC | 63 | 25.0 ± 5.0 | 1 | Rotigotine 1.125–4.5 mg/24 h | N/A | Rotigotine=34/49 (69) Placebo=6/14 (43) |
4 |
| Trenkwalder (2004)19 | P, R, DB, PC | 284 | 24.4 ± 5.8 | 12 | Ropinirole 0.25–4.0 mg/d | –3.0±1.1 | Ropinirole=78/146 (53) Placebo=56/138 (41) |
4 |
| Walters (2004)20 | P, R, DB, PC | 267 | 23.6 ± 5.9 | 12 | Ropinirole 0.25–4.0 mg/d | –2.5±1.1 | Ropinirole=78/131 (60) Placebo=53/135 (39) |
5 |
| Bogan (2006)21 | P, R, DB, PC | 381 | 22.0 ± 5.0 | 12 | Ropinirole 0.25–4.0 mg/d | –3.7±0.9 | Ropinirole=137/187 (73) Placebo=109/193 (56) |
5 |
| Inoue (2006)22 | P, R, DB, PC | 41 | N/A | 6 | Pramipexole 0.125–0.75 mg/d | –11.5±3.0 | Pramipexole=16/20 (80) Placebo=11/21 (52) |
3 |
| Partinen (2006)23 | P, R, DB, PC | 107 | 22.7 ± 4.1 | 3 | Pramipexole 0.125–0.75 mg/d | –9.2±1.7 | Pramipexole=65/86 (76) Placebo=9/21 (43) |
3 |
| Winkelman (2006)24 | P, R, DB, PC | 339 | 23.4 ± 5.1 | 12 | Pramipexole 0.25–0.75 mg/d | –4.3±1.1 | Pramipexole=183/254 (72) Placebo=44/85 (52) |
4 |
| Garcia-Borreguero (2007)25 | P, R, DB. PC | 270 | 25.4 | 8 | Sumanirole 0.5–4.0 mg/d | N/A | Sumanirole=104/212 (49) Placebo=26/51 (51) |
3 |
| Oertel (2007)26 | P, R, DB. PC | 341 | 28.0 ± 6.3 | 6 | Rotigotine 0.5–4 mg/24 h | N/A | Rotigotine=212/280 (76) Placebo=29/53 (55) |
5 |
| Oertel (2007)27 | P, R, DB. PC | 338 | 24.7 ± 5.2 | 6 | Pramipexole 0.125–0.75 mg/d | –6.6±1.1 | Pramipexole=141/224 (63) Placebo=37/114 (32) |
3 |
| RRL10001328 | P, R, DB, PC | 359 | 26.0 ± 4.4 | 12 | Ropinirole 0.5–6.0 mg/d | –4.1±1.0 | Ropinirole=124/175 (71) Placebo=92/184 (50) |
4 |
| ROP10189229 | P, R, DB, PC | 298 | 23.5 ± 6.2 | 12 | Ropinirole 0.25–4.0 mg/d | N/A | Ropinirole=92/152 (61) Placebo=76/146 (52) |
4 |
| SKF10146830 | P, R, DB, PC | 54 | 26.6 ± 5.3 | 7 | Ropinirole 0.25–4.0 mg/d | –9.9±2.9 | N/A | 3 |
CGI-I = Clinical Global Impression – Improvement scale; DB = double-blind; IRLS = International Restless Legs Syndrome Study Group scale; N/A=not available; P=prospective; PC=placebo control; R=randomized.